SCHEMBL19207261

SCHEMBL19207261

CC(C)(C)NC(=O)c1cc(-c2ccc(F)c(F)c2)nc(-c2ccnn2C(C)(C)C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
KDM5B Q9UGL1 1/20 0.38
KMO O15229 1/20 0.36
RIPK1 Q13546 1/20 0.35
LMNA P02545 1/20 0.35
CNR1 P21554 1/20 0.34
ALOX5AP P20292 3/20 0.34
FEN1 P39748 3/20 0.34
POLB P06746 2/20 0.34
AKT1 P31749 2/20 0.34
AKT2 P31751 2/20 0.34
ANO1 Q5XXA6 1/20 0.34
CSNK1E P49674 1/20 0.34
SGK1 O00141 1/20 0.33
ROCK2 O75116 1/20 0.33
RPS6KB1 P23443 1/20 0.33
PRKCQ Q04759 1/20 0.33
ROCK1 Q13464 1/20 0.33
RPS6KA1 Q15418 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19207308 0.92 KMO (0.39) KMORIPK1LMNAALOX5APFEN1
SCHEMBL19207300 0.92 CSNK1D (0.35) RIPK1LMNACNR1POLBCSNK1E
SCHEMBL19207305 0.91 CNR1 (0.41) KMORIPK1CNR1POLBANO1
SCHEMBL19207296 0.91 CNR2 (0.41) KDM4CKMOCNR1POLBANO1
SCHEMBL19207284 0.89 MAPT (0.40) KDM5AKDM4CKDM5BRIPK1LMNA
SCHEMBL29727602 0.87 KDM5A (0.39) KDM5AKDM4CKDM5BRIPK1CNR1
SCHEMBL19207304 0.87 CNR1 (0.45) RIPK1LMNACNR1
SCHEMBL19641923 0.87 KDM5A (0.39) KDM5AKDM4CKDM5BRIPK1CNR1
SCHEMBL19207339 0.86 CTRC (0.39) KDM5AKDM4CKDM5BRIPK1LMNA
SCHEMBL19207306 0.86 NR3C2 (0.37) KDM5AKDM4CKDM5BKMORIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108473462-B Pyrazole-pyridine derivatives as EAAT3 inhibitors 豪夫迈·罗氏有限公司 2021-06-22 CN claimed
EP-3411365-B1 PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2019-11-20 EP claimed
US-10457663-B2 Pyrazol-pyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2019-10-29 US claimed
US-20180339975-A1 PYRAZOL-PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-11-29 US claimed
CN-108473462-B Pyrazole-pyridine derivatives as EAAT3 inhibitors 豪夫迈·罗氏有限公司 2021-06-22 CN disclosed
EP-3411365-B1 PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2019-11-20 EP disclosed
EP-3411365-B1 PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2019-11-20 EP disclosed
US-10457663-B2 Pyrazol-pyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2019-10-29 US disclosed
US-10457663-B2 Pyrazol-pyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2019-10-29 US disclosed
EP-3411365-A1 PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS H. Hoffnabb-La Roche Ag (CH) 2018-12-12 EP disclosed
US-20180339975-A1 PYRAZOL-PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-11-29 US disclosed
WO-2017133990-A1 PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2017-08-10 WO disclosed
WO-2017133990-A1 PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2017-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10457663-B2 Pyrazol-pyridine derivatives MC3R, MC2R, DRD3 KDM5A 2241/4885KDM4C 2525/4885KDM5B 3827/4885
US-20180339975-A1 PYRAZOL-PYRIDINE DERIVATIVES MC3R, MC2R, DRD3 KDM5A 2241/4885KDM4C 2525/4885KDM5B 3827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.